The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 03, 2015

Filed:

Nov. 12, 2010
Applicants:

Celia Dominguez, Los Angeles, CA (US);

John Wityak, Carlsbad, CA (US);

Michael Prime, Oxfordshire, GB;

Stephen Martin Courtney, Oxfordshire, GB;

Christopher Yarnold, Oxfordshire, GB;

Frederick Brookfield, Oxfordshire, GB;

Richard Marston, Oxfordshire, GB;

Douglas Macdonald, Los Angeles, CA (US);

Inventors:

Celia Dominguez, Los Angeles, CA (US);

John Wityak, Carlsbad, CA (US);

Michael Prime, Oxfordshire, GB;

Stephen Martin Courtney, Oxfordshire, GB;

Christopher Yarnold, Oxfordshire, GB;

Frederick Brookfield, Oxfordshire, GB;

Richard Marston, Oxfordshire, GB;

Douglas Macdonald, Los Angeles, CA (US);

Assignee:

CHDI Foundation, Inc., New York, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/635 (2006.01); C07C 311/46 (2006.01); C07D 211/34 (2006.01); C07D 211/54 (2006.01); C07D 211/58 (2006.01); C07D 211/96 (2006.01); C07D 213/38 (2006.01); C07D 213/40 (2006.01); C07D 213/56 (2006.01); C07D 215/38 (2006.01); C07D 217/14 (2006.01); C07D 217/22 (2006.01); C07D 239/42 (2006.01); C07D 263/58 (2006.01); C07D 277/42 (2006.01); C07D 295/205 (2006.01); C07D 295/26 (2006.01); C07D 307/52 (2006.01); C07D 401/04 (2006.01); C07D 487/04 (2006.01); C07D 495/04 (2006.01);
U.S. Cl.
CPC ...
C07C 311/46 (2013.01); C07D 211/34 (2013.01); C07D 211/54 (2013.01); C07D 211/58 (2013.01); C07D 211/96 (2013.01); C07D 213/38 (2013.01); C07D 213/40 (2013.01); C07D 213/56 (2013.01); C07D 215/38 (2013.01); C07D 217/14 (2013.01); C07D 217/22 (2013.01); C07D 239/42 (2013.01); C07D 263/58 (2013.01); C07D 277/42 (2013.01); C07D 295/205 (2013.01); C07D 295/26 (2013.01); C07D 307/52 (2013.01); C07D 401/04 (2013.01); C07D 487/04 (2013.01); C07D 495/04 (2013.01); C07C 2101/14 (2013.01);
Abstract

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.


Find Patent Forward Citations

Loading…